[1] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[2] |
YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin.
Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
|
[3] |
ZHU Yuanchao, ZHANG Yatong, HU Xin.
Principles and measures of medication risk management in the elderly
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1031-1034.
|
[4] |
LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping.
Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
|
[5] |
YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing.
Safety of sugammadex for reversal of neuromuscular block based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
|
[6] |
HAO Xiaohui, ZHANG Ping, WU Lulu, WANG Lihua.
Mining and analysis of ixazomib citrate capsules safety signals based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1427-1431.
|
[7] |
JIANG Jiandong.
Development and clinical safety of paediatric medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 1-6.
|
[8] |
WANG Juli, ZHANG Xiaomeng, ZHANG Bing, LYU Jintao.
Safety of medications for cardiovascular diseases in community clinics
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 744-748.
|
[9] |
REN Yuqin, LI Xin, YU Min, SU Yuwen.
Safety evaluation and comparative analysis of rituximab and adalimumab based on openFDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 752-756.
|
[10] |
ZHANG Chi.
Data mining of adverse drug events of alirocumab from openFDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 684-691.
|
[11] |
CUI Xiangli, ZHANG Zhiqi, SUN Liying, GUO Mingxing, ZENG Zhigui, XU Wanyi.
Leflunomide-induced hepatotoxicity: data analysis based on the FDA adverse event reporting system
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 426-431.
|
[12] |
HUANG Liting, TANG Zaixiang, BAI Lu, SHI Guanhong, JIANG Yiguo.
Adverse reactions of benzodiazepines based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1223-1227.
|
[13] |
ZHAO Xiaohong, GUO Mingxing, WANG Xiaojian, LIN Jianrui, CUI Xiangli.
Risk signal mining related to lenvatinib based on the US FDA adverse event reporting system
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1233-1237.
|
[14] |
SHA Mingquan, LI Nannan, XIA Wenjing, WEI Qun, WEN Baoshu.
Research and reflection on regulatory science developments of U.S. FDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1055-1059.
|
[15] |
SONG Mingyue, ZHANG Ran, WU Zhiang.
Influencing factors of quality risk management of drug recall in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1087-1090.
|